Editor's note - Page 10 of 21 - Express Pharma

Own up, course correct and move on

Post USTR Special 301 Report, pragmatism wins over confrontation?

India on USTR’s Priority ~ Watch List again

Cracking the cGMP code

Patient care apps serve a purpose, but need to be closely monitored

Stree Shakti in the CDSCO!

USTR review could mean tough times ahead

Beyond the budget

Will a toothless drug price watchdog be good or bad for business?

Out with the old, on with the new